Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone

1. A solid form of compound 1,

wherein said solid form is a crystalline form A2,

wherein said form A2 is characterized by the following 2θ XRPD peaks at 4.7, 9.4, 15.0, 17.5, 17.9, 19.0, 19.7, 20.6 and 23.4±0.2 degrees under the following conditions: monochromatic Cu-Kα 1 radiation, λ=1.5406 Å.

2. A solid form of compound 1,

which is a solid form Malonate-NF1 of a malonate salt of compound 1 characterized by two or more 2θ XRPD peaks at 7.6, 15.6, or 25.0±0.2 degrees under the following conditions: monochromatic Cu-Kα 1 radiation, λ=1.5406 Å.

3. The Malonate-NF1 salt of claim 2 , characterized by four or more 2θ XRPD peaks at 7.6, 12.9, 15.6, 16.2, 20.7, 20.9, 22.4, or 25.0±0.2 degrees.

4. A solid form of compound 1,

which is a solid form Succinate-NF1 of a succinate salt of compound 1 characterized by two or more 2θ XRPD peaks at 6.7, 19.2, or 20.7±0.2 degrees under the following conditions: monochromatic Cu-Kα 1 radiation, λ=1.5406 Å.

5. The Succinate-NF1 salt of claim 4 , characterized by four or more 2θ XRPD peaks at 6.7, 14.7, 15.5, 19.2, 20.7, 21.6, or 21.9±0.2 degrees.

6. A solid form of compound 1,

which is a solid form Oxalate-NF1 of an oxalate salt of compound 1 characterized by two or more 2θ XRPD peaks at 7.5, 17.8, or 19.5±0.2 degrees under the following conditions: monochromatic Cu-Kα 1 radiation, λ=1.5406 Å.

7. The Oxalate-NF1 salt of claim 6 , characterized by four or more 2θ XRPD peaks at 7.5, 9.0, 16.1, 17.3, 17.8, 19.5, 20.3 or 23.8±0.2 degrees.

8. The solid form of claim 1 , characterized as a mixture of crystalline forms A1 and A2;

wherein said crystalline form A1 is characterized by the following 2θ XRPD peaks at 4.8, 9.5, 15.1, 17.4, 18.1, 20.0, and 23.8±0.2 degrees under the following conditions: monochromatic Cu-Kα 1 radiation, λ=1.5406 Å.

9. A pharmaceutical composition, comprising:

a solid form of compound 1 of claim 1 , and

a pharmaceutically acceptable adjuvant, carrier, or vehicle.

10. A method for treating a BTK-mediated disorder in a patient in need thereof, comprising:

administering to said patient a solid form of compound 1 of claim 1 ;

wherein said BTK-mediated disorder is systemic lupus erythematosus (SLE), multiple sclerosis, or rheumatoid arthritis.

11. A solid form of compound 1,

which is a solid form Fumarate-NF1 of a fumarate salt of compound 1 characterized by four or more 2θ XRPD peaks at 6.7, 14.8, 15.2, 16.7, 18.3, 19.3, or 20.8±0.2 degrees under the following conditions: monochromatic Cu-Kα 1 radiation, λ=1.5406 Å.

12. A solid form of compound 1,

which is a solid form Maleate-NF1 of a maleate salt of compound 1 characterized by four or more 2θ XRPD peaks at 10.5, 11.5, 17.9, 18.4, 19.0, 20.3, 20.5, or 24.7±0.2 degrees under the following conditions: monochromatic Cu-Kα 1 radiation, λ=1.5406 Å.

13. A solid form of compound 1,

which is a solid form Citrate-NF1 of a citrate salt of compound 1 characterized by four or more 2θ XRPD peaks at 7.5, 12.1, 13.8, 15.0, 16.3, 17.7, 20.3, or 20.8±0.2 degrees under the following conditions: monochromatic Cu-Kα 1 radiation, λ=1.5406 Å.